METHODS: We engaged 25 men in semi-structured telephone interviews focusing on their initial experience transitioning from IMPACT to ACA-based insurance coverage. Interviews were recorded and transcribed for review. Transcripts were coded for themes around patient experience with IMPACT, the insurance enrollment process, and initial experience with comprehensive health insurance.
METHODS: We engaged 25 men in semi-structured telephone interviews focusing on their initial experience transitioning from IMPACT to ACA-based insurance coverage. Interviews were recorded and transcribed for review. Transcripts were coded for themes around patient experience with IMPACT, the insurance enrollment process, and initial experience with comprehensive health insurance.
RESULTS: Demographic and quality of life are summarized in Table 1 . Four thematic domains were identified: 1) insurance enrollment process, 2) attributes and challenges of care in IMPACT, 3) attributes and challenges of care with ACA-based insurance, and 4) overall changes in care after insurance enrollment. Major findings are presented in Table 2 . Twenty-three men enrolled in Medicaid. Fifteen men reported completing a paper application with 24% of patients receiving help from social workers and 20% from family members. Insurance coverage began more than 3 months after completing the application 40% of the time. Ten men reported that navigating CaP treatment was easier with IMPACT. Twelve patients reported improved access to care with insurance, while 6 patients reported increased health care costs and 5 reporting decreased health care costs after insurance enrollment. 24% of patients were able to keep the same primary doctor and urologist after enrollment.
CONCLUSIONS: Low-income men gaining insurance coverage under the ACA are predominantly enrolling in Medicaid. They face delays in coverage and interruptions in continuity of care, but report improved access. The relative burden of healthcare costs after gaining insurance is mixed. METHODS: The distribution of race within 220 Medicare Shared Savings Program ACOs was ascertained from the 2013 MSSP Public Use File. The ZIP Code Tabulation Areas (ZCTA) in each ACO were weighted according to its representation within the ACO. The distribution of race was then calculated for the ZCTAs that an ACO covered according to the 2010 U.S. Census and compared to the distribution in the ACO. The degree of disparity was calculated as: (% minority in community e % minority in ACO) / % minority in community.
RESULTS: Overall, the median disparity between the representation of all minorities in the community compared to the ACO was 41.6% [interquartile range (IQR) 25-51%, see Fig.] . Among black beneficiaries, the median disparity was 27.1% (IQR 11-48%). There was a median 65.6% disparity (IQR 52-79%) among Hispanics and 57.5% disparity (IQR 43-67%) among Asians. The vast majority of ACOs exhibited large degrees of disparity, with 77.7% and 64.6% of the ACOs having a disparity of more than 50% among Hispanic and Asian communities, respectively. Thirteen ACOs (5.9%) had a large negative disparity, where the proportion of minorities within the ACOs was larger than in the community. Federally qualified health centers (FQHC) were e124 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Friday, May 12, 2017 largely represented in these ACOs with a negative disparity; on average there were 11 FQHC represented in ACOs with a negative disparity compared to 0.9 FQHC in ACOs with a positive disparity (p<0.01). CONCLUSIONS: Our findings show that all minority patients are consistently under-represented in early MSSP ACOs. This raises concerns that minority patients in the community have less access to physicians and provider groups who participate in ACOs and the potential benefits conferred by this delivery system innovation. The development of ACOs may ultimately exacerbate known racial disparities germane to urologic practice unless incentives are aligned to promote inclusion of minority populations in alternative payment models.
Source of Funding: American Cancer Society (MSRG-15-103-01-CHPHS to MJR), AUA/Urology Care Foundation Rising Stars in Urology Research Program

PD06-09 HEALTHCARE DISPARITIES: DO MEDICAID PATIENTS HAVE LONGER WAIT TIMES FOR OUTPATIENT UROLOGICAL EVALUATION?
Wai Lee*, Andrew Chen, Ramsey Al-Khalil, Tal Cohen, William T. Berg, Wayne C. Waltzer, Jason Kim, Howard L. Adler, Stony Brook, NY INTRODUCTION AND OBJECTIVES: Insurance status has been demonstrated to be a barrier to prompt urological care. Telephone surveys reveal that substantially fewer urologists accept Medicaid compared to Medicare or private insurance. There is a paucity of urologic literature evaluating discrepancies in wait times for Medicaid patients versus other forms of insurance. We sought to evaluate wait time disparities in academic urology programs for Medicaid compared to Medicare patients.
METHODS: The cohort was identified from the online listing of all ACGME accredited urology residency programs. An IRB-approved standardized script was used to contact each institution to determine if they accepted Medicaid patients. For institutions that accepted Medicaid, separate calls were made to establish the earliest appointment time available for a fictional patient with Medicaid and then Medicare insurance. Discrepancies in wait times between insurance type were compared. All statistical analysis was performed using SPSS v24.0.
RESULTS: All 131 ACGME accredited academic urology programs were surveyed. Of these, 10 (7.6%) did not accept new patients with Medicaid insurance. 13 institutions (9.92%) declined to participate in our study. There were 108 academic urology clinics in our final analysis. Of these, 59% (n¼64) had longer wait times for Medicaid patients. Overall, there was a significant difference (p<0.001) between the mean wait times for a new patient visit with Medicare (23 days, STD 20.8) versus Medicaid (35 days, STD 27.5). For Medicaid appointments, 73.1% (n¼79) were scheduled in resident run clinics only. When stratified by AUA section, academic urology programs had longer average wait times for Medicaid patients when compared to Medicare patients. However, only the New York (n¼16, 26.8 vs 10.1 days, p¼0.022) and Southeastern (n¼23, 41.8 vs 26.8 days, p¼0 .050) sections had significantly longer wait times (Table 1) .
CONCLUSIONS: Our data suggests that patients with Medicaid experience longer wait times for their initial urological evaluation. Barriers to timely clinical evaluation have been cited as a reason for emergency room visitation. Awareness of such disparities in urologic care is an early step toward improving the quality of healthcare for all individuals.
Source of Funding: none
PD06-10 PATIENT REFUSAL OF NEO-ADJUVANT CHEMOTHERAPY FOR MUSCLE INVASIVE BLADDER CANCER
INTRODUCTION AND OBJECTIVES: While use of neo-adjuvant chemotherapy (NAC) prior to radical cystectomy (RC) for muscleinvasive bladder cancer (MIBC) has been steadily increasing over the last decade, the majority of patients are not receiving NAC. Little is known about the reasons as to why these patients do not receive NAC. Our objective was to evaluate the rate of patient refusal of NAC, and examine descriptive characteristics associated with patient refusal of NAC.
METHODS: Using the National Cancer Data Base, patients who underwent RC between 2004-2013 for a diagnosis of cT2 MIBC were included. Among patients who did not receive NAC, patients were categorized as (i) having been recommended NAC and refused, or (ii) not recommended NAC due to patient risk factors. Bivariable analysis was used to determine associations for not receiving NAC between age, gender, race, income level, insurance status, education level, type of facility, distance to oncology provider, and trend over time.
RESULTS: Of 8298 patients who underwent cystectomy, 524 did not receive NAC and had complete data regarding reasons for
